Penn Bioethics Seminar (PBS): Steve Joffe, MD, MPH Chair, Dept. of Medical Ethics and Health Policy

12:00pm - 1:00pm • Hybrid 1402 Blockley Hall, 423 Guardian Drive (and virtual via Zoom)

2023-07-11 12:00:00 2023-07-11 13:00:00 America/New_York Penn Bioethics Seminar (PBS): Steve Joffe, MD, MPH Chair, Dept. of Medical Ethics and Health Policy Steve Joffe, MD, MPH Chair, Department of Medical Ethics and Health Policy Chief, Division of Medical Ethics Over the last two decades, the pace of FDA approvals of cancer drugs has dramatically accelerated. Most of the focus during this period has been on the development and approval of drugs for recurrent or advanced disease. While such drugs may extend life, alleviate symptoms, and improve quality of life, they are rarely curative. In contrast, much of the burden of cancer, and much of the opportunity to increase cure rates, lies in improving treatment for patients with newly diagnosed, limited-stage disease. In this presentation, we will report preliminary results from an analysis of all FDA drug approvals for solid tumors since 2006, with particular focus on the proportions of new indications that were for limited-stage, newly diagnosed versus advanced or recurrent disease. Lunch provided for in-person attendees Livestreaming available via Zoom Hybrid 1402 Blockley Hall, 423 Guardian Drive (and virtual via Zoom) Penn Medical Ethics

Steve Joffe, MD, MPH

Chair, Department of Medical Ethics and Health Policy
Chief, Division of Medical Ethics

Over the last two decades, the pace of FDA approvals of cancer drugs has dramatically accelerated. Most of the focus during this period has been on the development and approval of drugs for recurrent or advanced disease. While such drugs may extend life, alleviate symptoms, and improve quality of life, they are rarely curative. In contrast, much of the burden of cancer, and much of the opportunity to increase cure rates, lies in improving treatment for patients with newly diagnosed, limited-stage disease. In this presentation, we will report preliminary results from an analysis of all FDA drug approvals for solid tumors since 2006, with particular focus on the proportions of new indications that were for limited-stage, newly diagnosed versus advanced or recurrent disease.